TAJNIŠTVO 81. DANA DIJABETOLOGA/
|
|
- Milo McGee
- 5 years ago
- Views:
Transcription
1
2 Hrvatsko društvo za dijabetes i bolesti metabolizma Hrvatskog liječničkog zbora / Croatian Society for Diabetes and Metabolic Disorders of the Croatian Medical Association PREDSJEDNIK/PRESIDENT doc.dr.sc. Dario Rahelić PODPREDSJEDNIK/VICEPRESIDENT doc.dr.sc. Sanja Klobučar Majanović TAJNIK/SECRETARY Ana Majić, dr.med. UPRAVNI ODBOR/EXECUTIVE COMMITTEE doc.dr.sc. Miro Bakula, dr.med. Marin Deškin, dr.med. prim. Igor Bjelinski, dr.med. doc.dr.sc. Mladen Krnić, dr.med. doc.dr.sc. Silvija Canecki Varžić, dr.med. TAJNIŠTVO 81. DANA DIJABETOLOGA/SECRETARY OF THE 81 st DAYS OF DIABETOLOGISTS Zavod za endokrinologiju, dijabetes i kliničku farmakologiju Klinička bolnica Dubrava / University hospital Dubrava Av. Gojka Šuška 6, HR Zagreb Tel , Fax simpozij@hddbm.hr TEHNIČKA ORGANIZACIJA/TECHNICAL ORGANIZER A.T.I. d.o.o. Zadarska 15, HR Pula OIB , ID KOD HR-AB Tel , Fax
3 Pozdravna riječ Poštovane kolegice i kolege, osobita mi je čast i zadovoljstvo zaželjeti vam dobrodošlicu na Simpozij 81. Dani dijabetologa s međunarodnim sudjelovanjem u prelijepom povijesnom gradu Splitu. Ovaj puta glavna tema je organizacija skrbi osoba sa šećernom bolešću u Republici Hrvatskoj, a sudionici će imati priliku u raspravi iznijeti vlastite stavove i iskustva. Osim priznatih stručnjaka iz Hrvatske, pozvani su i gosti predavači iz inozemstva. Svojim sudjelovanjem i prikazom svog rada aktivno doprinosite uspjehu 81. Dana dijabetologa. Dobrodošli u Split doc.dr.sc. Dario Rahelić Predsjednik Hrvatskog društva za dijabetes i bolesti metabolizma Hrvatskog liječničkog zbora
4 Welcome Dear Colleagues, It is a special honor and my pleasure to welcome you to the Symposium 81 st Days of diabetologists with international participation in the beautiful historical city of Split. This time, the main topic is the organization of the care of people with diabetes in the Republic of Croatia, and the participants will have the opportunity to present their own attitudes and experiences. In addition to acknowledged experts from Croatia, we have invited guest lecturers from abroad. With your participation and presentation of your work, you actively contribute to the success of the 81 st days of diabetologists. Welcome to Split Asst. prof. Dario Rahelić, MD, PhD, FACE, FRCP Edin. President of the Croatian Society for Diabetes and Metabolic Disorders of the Croatian Medical Association
5 Program/Programme PETAK/FRIDAY :00 Okupljanje u Zračnoj luci Franjo Tuđman, Zagreb/ Meeting at Franjo Tuđman Airport, Zagreb 14:35 Let za Split/Flight to Split 15:30 Organizirani prijevoz Zračna luka Split Hotel Radisson Blu, Split/ Organized transfer from Split Airport to Hotel Radisson Blu INVITED INTERNATIONAL SPEAKERS Moderator/Chairman: D. Rahelić 17:30 17:50 The care of patients with diabetes and cognitive impairments, B.Mankovsky (Ukrajina/Ukraine) 17:50 18:10 Do we have limitations in reaching ideal metabolic targets in diabetic patients, L. Danilova (Bjelorusija/Belarus) 18:10 18:15 Rasprava/Discussion BLOK 1 Moderatori/Chairmen: M. Radman, T. Tičinović Kurir, M. Krnić 18:15 18:30 Organizacija skrbi osoba sa šećernom bolešću u KBC-u Split/ Organization of care for people with diabetes in the Clinical Hospital Centre Split, T. Tičinović Kurir 18:30 18:45 Organizacija skrbi o dijabetičkom bolesniku - iz ugla pacijenta/ Organization of care for people with diabetes from the patient s view, M. Radman 18:45 19:00 Najracionalnije liječenje Adherentno liječenje/ The most rational terapy Asherent therapy, M. Krnić 19:00 19:15 Da li smo sa sadašnjim znanjem spremni suočiti se s izazovom liječenja šećerne bolesti tipa 2 u svom subkliničkom obliku predijabetesu/are we ready to face the challenges in treatment of subclinical type 2 diabetes, S. Kokić 19:15 19:30 Rasprava/Discussion 19:30 Otvorenje simpozija/symposium Opening 20:00 Večera/Dinner
6 Program/Programme SUBOTA/SATURDAY BLOK 2 Moderatori/Chairmen: V. Božikov, M. Jandrić Balen, D. Rahelić 08:00 08:15 Mogućnost racionalnog praćenja dijabetičkih pacijenata u udomiteljskim obiteljima i obiteljskim domovima/ Possibility of rational monitoring of patients with diabetes in foster families and family homes, B. Miškić 08:15 08:30 Uloga dijabetologa u racionalnom pristupu dijabetičkom bolesniku/ The role of the diabetologist in a rational approach to a patient with diabetes, M. Jandrić Balen 08:30 08:45 Jesmo li zaboravili važnost ispravne aplikacije inzulina?/ Have we forgotten the importance of the correct insulin application?, S. Majanović Klobučar 08:45 09:00 Fiksne kombinacije u liječenju šećerne bolesti tipa 2/ Fixed combinations in treatment of type 2 diabetic patients, M. Berković Cigrovski 09:00 09:15 Rasprava/Discussion BLOK 3 Moderatori/Chairmen: I. Pavlić Renar, M. Vrca Botica, V. Škrabić 09:15 09:30 Prevencija dijabetičke ketoacidoze u djece i adolescenata/ Prevention of diabetic ketoacidosis in children and adolescents, V. Škrabić 09:30 09:45 Skrb o šećernoj bolesti tko to radi?/diabetes care who does it?, I. Pavlić Renar 09:45 10:00 Strukturirani model skrbi o šećernoj bolesti tipa 2 u primarnoj zaštiti: procjena kvalitete skrbi/structured model of type 2 diabetes care in primary care: quality assessment, M. Vrca Botica 10:00 10:15 Rasprava/Discussion 10:15 10:45 Stanka za kavu/coffee break
7 Program/Programme SUBOTA/SATURDAY :45 11:45 Satelitski simpozij Novo Nordisk Hrvatska / Satellite Symposium Novo Nordisk Hrvatska Možemo li učiniti više? Terapijske opcije u liječenju šećerne bolesti tipa 2/Can we do more? Therapeutic options in treatment of diabetes mellitus type 2 Kardiovaskularni rizik u šećernoj bolesti tipa 2/Cardiovascular risk in diabetes mellitus type 2, G. Mirošević Implementacija rezultata LEADER ispitivanja u kliničku praksu/ Implementation of LEADER results in clinical practice, M. Bakula Jesu li svi bazalni inzulini isti?/are all basal insulins the same?, T. Matić BLOK 4 Moderatori/Chairmen: V. Goldoni, D. Jurišić Eržen, Ž. Crnčević Orlić 11:45 12:00 Nova analiza troškova liječenja osoba sa šećernom bolešću u Republici Hrvatskoj/New cost analysis of treating people with diabetes in Croatia, T. Šarić 12:00 12:15 Standardi skrbi osoba sa šećernom bolešću u Republici Hrvatskoj/ Standards of care for people with diabetes in Croatia, D. Rahelić 12:15 12:30 Racionalni pristup injektibilnoj terapiji u tipu 2 šećerne bolesti/ Rational approach to injectable therapy in type 2 diabetes, D. Jurišić Eržen 12:30 12:45 Racionalni pristup u izboru antihiperglikemika druge linije/ Rational approach in choosing the second line antihyperglycaemic drug, M. Bakula 12:45 13:00 Skrb osoba sa šećernom bolešću starije životne dobi/care for elderly people with type 2 diabetes, Ž. Crnčević Orlić 13:00 13:15 Rasprava/Discussion 13:15 14:00 Satelitski simpozij Abbott / Satellite Symposium Abbott New way of glucose monitoring: so easy with FreeStyle Libre, W. Młynarski (Poljska/Poland) Italian best practice with FGM: how to leverage AGP, A. Di Flaviani (Italija/Italy)
8 Program/Programme SUBOTA/SATURDAY :00 14:30 Satelitski simpozij Sanofi Aventis / Satellite Symposium Sanofi Aventis Bazalni inzulini dijalog između kliničkih dokaza i kliničke prakse/ Basal insulin- an essential dialogue between evidence and clinical practice Nova generacija bazalnih analoga potrebe, mogućnosti, rješenja/ New generation of basal analogues is there a need, what are the possibilities and solutions?, T. Tičinović Kurir Produljeno djelovanje nove generacije bazalnih inzulina - prednosti za bolesnike sa ŠBT1/Could a basal insulin with a more stable and prolonged PK/PD profile bring additional benefits to patients with T1?, M. Gradišer 14:30 15:30 Ručak/Lunch BLOK 5 Moderatori/Chairmen: M. Bakula, S. Canecki Varžić, S. Balić 15:30 15:45 Regionalni centar za dijabetes, endokrinologiju i bolesti metabolizma Osijek: / Regional Centre for Diabetes, Endocrinology and Metabolic Diseases Osijek: , S. Canecki Varžić 15:45 16:00 Što je racionalna terapija u tipu 1 šećerne bolesti/what is rational therapy in type 1 diabetes, I. Bjelinski 16:00 16:15 Pristup bolesniku s dijabetesom i bolesti jetre/approach to a patient with diabetes and liver disease, D. Herman Mahečić 16:15 16:30 Možemo li individualnom MNT utjecati na racionalizaciju troškova? Primjeri iz prakse/can an individual MNT affect rationalization of costs? Examples from practice, E. Pavić 16:30 16:45 Kontinuirano intenziviranje terapijskog pristupa u tipu 2/Continuous intensification of the therapeutic approach in type 2 diabetes, M. Deškin 16:45 17:00 Rasprava/Discussion
9 Program/Programme SUBOTA/SATURDAY :00 17:30 Satelitski simpozij Takeda / Satellite Symposium Takeda Takeda u srcu dijabetesa/takeda in the heart of diabetes Što smo još saznali iz podataka Examine studije/ What more did we learn from EXAMINE study data, D. Jurišić Eržen Što smo naučili o pioglitazonu u proteklih 18 godina/what did we learn about pioglitazone in the last 18 years, Z. Vučinović Prikaz pacijenta sa visokim KV rizikom liječenog Incresync-om/ Case study high CV risk patient with Incresync therapy, M. Jurin 17:30 18:00 Stanka za kavu/coffee break 18:00 18:30 Satelitski simpozij Boehringer Ingelheim/Satellite Symposium Boehringer Ingelheim Šećerna bolest tipa 2 i komorbiditeti prednosti novih lijekova/ Type 2 diabetes and comorbidities new therapy advantages, T. Tičinović Kurir, M. Bakula BLOK 6 Moderatori/Chairmen: Ž. Metelko, M. Radman, B. Miškić 18:30 18:45 Rana inzulinizacija u tipu 2 šećerne bolesti/early insulinization in type 2 diabetes, I. Kajinić 18:45 19:00 Pristup bolesniku s novootkrivenim dijabetesom u Dnevnoj bolnici OB Šibenik/Approach to a patient with newly diagnosed diabetes in daily hospital in the General Hospital Sibenik, M. Jurin 19:00 19:15 Rasprava/Discussion 21:00 Večera/Dinner
10 Program/Programme NEDJELJA/SUNDAY BLOK 7 Moderatori/Chairmen: S. Klobučar Majanović, Ž. Metelko, T. Tičinović Kurir 09:00 09:15 Možemo li premostiti procjep između rezultata liječenja tijekom kontrolirano-slučajno odabranih bolesnika i tijekom svakodnevnog liječenja bolesnika na modelu tipa 2 šećerne bolesti/can we cross the gap between the results of treatment during controlled-randomly selected patients and during the day-to-day treatment of patients with type 2 diabetes, Ž. Metelko 09:15 09:30 Posttransplantacijska šećerna bolest/posttransplant diabetes mellitus, E. Pape Medvidović 09:30 09:45 Terapijski pristup oboljelima od šećerne bolesti tipa 2 u O.B. Dr. Ivo Pedišić Sisak/Therapeutic approach to patients with type 2 diabetes in the General Hospital Dr Ivo Pedisic Sisak, S. Slošić Weiss 09:45 10:00 Racionalno liječenje šećerne bolesti tipa 2 osvrt iz moje perspektive/rational treatment of type 2 diabetes - a review from my perspective, J. Jelić 10:00 10:15 Da li smo odrasli dovoljno za promjene koje nas očekuju?/ Are we grown enough for the expected changes?, D. Fabris Vitković 10:15 10:30 Rasprava/Discussion 10:30 11:00 Stanka za kavu/coffee break BLOK 8 Moderatori/Chairmen: N. Car, V. Božikov, T. Tičinović Kurir 11:00 11:15 Liječenje necrobiosis lipoidica pomoću tacrolimusa/ The treatment of necrobiosis lipoidica with tacrolimus, N. Car 11:15 11:30 Racional(ni)ja uporaba lijekova u liječenju šećerne bolesti tipa 2/ (More) Rational drug use in the treatment of type 2 diabetes, N. Gojo Tomić 11:30 11:45 Uloga dijabetologa u udruzi dijabetičkih bolesnika da li se uključiti?/the role of diabetologist in a diabetic patient association - to be involved?, M. Prašek
11 Program/Programme NEDJELJA/SUNDAY :45 12:00 Može li inzulinska rezistencija biti okidač za nastanak autoimune bolesti štitnjače?/can insulin resistance be the trigger for autoimmune thyroid disease?, G. Mirošević 12:00 12:15 Racionalno zbrinjavanje oboljelih od šećerne bolesti u Županijskoj bolnici Čakovec/Rational care of diabetic patients in the County Hospital Čakovec, A. Marić 12:15 12:30 Racionalni pristup - krenimo od temelja/rational approach let s start from the beginning, A.M. Liberati Čizmek 12:30 12:45 Rasprava/Discussion 12:45 13:45 Sastanak Društva za dijabetes i bolesti metabolizma Hrvatskog liječničkog zbora/meeting of the Croatian Society for Diabetes and Metabolic Disorders 13:45 15:00 Ručak/Lunch 17:30 Organizirani prijevoz u Zračnu luku Split (let za Zagreb u 19:50)/ Organized transfer to Split Airport (flight to Zagreb at 19:50)
12 NOTES
13 NOTES
14
15
16
17
18
19
20 TRESIBA jednom dnevno DJELOVANJE DULJE OD 42 SATA 5,6 NOVI PODACI ZA TIP 1 i TIP 2 1,2,5 Uspje no sni enje HbA 1c 3,4 Manji rizik od hipoglikemija u odnosu na inzulin glargin 100U 1,2 Fleksibilno vrijeme doziranja u bilo koje doba dana, kada je potrebno 5...jednom dnevno. Referencije: 1. Lane WS, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, Nielsen TS, Warren ML. SWITCH 1: Reduced hypoglycaemia with insulin degludec (IDeg) vs insulin glargine (IGlar), both U100, in patients with T1D at high risk of hypoglycaemia: a randomised, double-blind crossover trial. Abstract presented at the 2. Wysham CH, Bhargava A, Chaykin LB, De La Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P. SWITCH 2: Reduced hypoglycaemia with insulin degludec (IDeg) vs insulin glargine (IGlar), both U100, in patients with June 10-14; New Orleans, LA. Poster 90-LB. 3. Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR on behalf of the BEGIN Basal Bolus Type 1 trial investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal Bolus Type 1): 2-year results of a randomized clinical trial. Diabetic Medicine 2013; 30: Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C on behalf of the BEGIN Once Long Trial Investigators. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabetic Medicine 2013; 30: T va lijeka 6. Jonassen I, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharmaceutical Research 2012;29(8): FlexTouch, NovoFine, NovoTwist i Tresiba A/S, Danska. Datum pripreme: HR/TB/0316/0066a SAMO ZA ZDRAVSTVENE RADNIKE U Novo Nordisku mijenjamo dijabetes. U pristupu razvoju lijekova, u predanosti da poslujemo s dobiti i eticno te u potrazi za lijekom. degludek inzulin (tehnologija rdnk) injekcija
POZDRAVNA RIJEČ Welcoming address
PROGRAM/ PROGRAMME POZDRAVNA RIJEČ Welcoming address Poštovane kolegice i kolege, osobita mi je čast i zadovoljstvo pozdraviti Vas i zaželiti Vam dobrodošlicu na Simpoziju 78. Dani dijabetologa Hrvatske
More informationInternational Diabetes Summit
International Diabetes Summit Type 2 Diabetes - Future Directions Hotel Valamar Lacroma / Dubrovnik / Croatia / September 5 th- 7th, 2014 Supported by Croatian Association for Diabetes and Metabolic Disorders
More informationRADNO POVJERENSTVO KONGRESA CONGRESS COMMITTEES
RADNO POVJERENSTVO KONGRESA CONGRESS COMMITTEES PREDSJEDNIK PRESIDENT prof.dr.sc. Željka Crnčević Orlić POTPREDSJEDNIK VICEPRESIDENT prof.dr.sc. Milan Vrkljan TAJNIK SECRETARY doc.dr.sc. Sanja Klobučar
More informationDiabetology & Metabolic Syndrome. Open Access SHORT REPORT
https://doi.org/10.1186/s13098-018-0321-x Diabetology & Metabolic Syndrome SHORT REPORT Open Access The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously
More informationChristopher Sorli Mark Warren David Oyer Henriette Mersebach Thue Johansen Stephen C. L. Gough
Drugs Aging (2013) 30:1009 1018 DOI 10.1007/s40266-013-0128-2 ORIGINAL RESEARCH ARTICLE Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with
More informationThe clinical trial programme for insulin degludec (IDeg) is the largest reported
supplement to Journal of the association of physicians of india january 2014 VOL. 62 21 Treating to Target in Type 2 Diabetes : The BEGIN Trial Programme Subhash K Wangnoo 1, Subhankar Chowdhury 2, PV
More informationMedium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus
Drugs R D (214) 14:133 138 DOI 1.17/s4268-14-48-6 ORIGINAL RESEARCH ARTICLE Medium-Term Effects of Insulin ludec on Patients with Type 1 Diabetes Mellitus Rie Nakae Yoshiki Kusunoki Tomoyuki Katsuno Masaru
More informationNew Drug Evaluation: Insulin degludec, subcutaneous injection
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOpinion 2 April TRESIBA 100 U/ml, solution for injection in prefilled pen B/5 pre-filled pens of 3 ml (CIP: )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 2 April 2014 TRESIBA 100 U/ml, solution for injection in prefilled pen B/5 pre-filled pens of 3 ml (CIP: 34 009 268
More informationMany people with type 2 diabetes
Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring
More informationRe-Submission: Published 10 March February 2014
Re-Submission: insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 07 February
More informationS. W. Park 1, W. M. W. Bebakar 2, P. G. Hernandez 3, S. Macura 4, M. L. Hersløv 5 and R. de la Rosa 6. Abstract. Introduction
DIABETICMedicine Research: Treatment Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST â : SIMPLE USE) S. W. Park 1, W. M. W.
More informationinsulin degludec (Tresiba ) is not recommended for use within NHS Scotland.
insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish
More informationAmerican Diabetes Association 76 th Scientific Sessions. Investor and analyst event. New Orleans, 13 June Slide 1
Slide 1 American Diabetes Association 76 th Scientific Sessions Investor and analyst event New Orleans, 13 June 216 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk
More informationJournal of Diabetes, Endocrinology and Metabolic Diseases
Vol. 44 No. 4 (pp. 97-126) 2015 / Zagreb, December 2016 vol. 44 no. 4 p.p. 97-126 2015 Journal of Diabetes, Endocrinology and Metabolic Diseases VUK VRHOVAC UNIVERSITY CLINIC, ZAGREB, DAMA - DIABETOLOGY
More informationSwitching from insulin glargine to insulin degludec: Safety and efficacy in Colombian adolescents with type 1 diabetes
Diabetes Management Switching from insulin glargine to insulin degludec: Safety and efficacy in Colombian adolescents with type 1 diabetes Myrey Siuffi D* ABSTRACT Introduction: Degludec (Ideg) is an ultra-long
More informationA New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes
A New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes Reviewed by Dawn Battise, PharmD STUDIES Initiating insulin degludec (study A): Zinman B, Philis-Tsimikas A, Cariou B, Handelsman
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine regardless of the hypoglycaemia definition
More informationComparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study
Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study Mizuho Yamabe 1, Mami Kuroda 1, Yasuyo Hirosawa 1,HiromiKamino 1, Haruya Ohno
More informationTarget Audience. approach this patient case scenario, including identifying an
Activity Overview In this case-based webcast, meet LaWanda, a 57-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 8.4%, she is currently taking basal insulin and fast-acting insulin,
More informationAuthor proof done. Insulin degludec. Vishakha V. Jain, Omprakash Gupta
Review Article Author proof done Insulin degludec Vishakha V. Jain, Omprakash Gupta Abstract Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues
More informationInsulin degludec The impact of a new basal insulin on care in type 2 diabetes
primary care diabetes 8 (2014) 119 125 Contents lists available at ScienceDirect Primary Care Diabetes journal homepage: http://www.elsevier.com/locate/pcd Original research Insulin degludec The impact
More informationCLINICAL TRIAL. Keywords Basal bolus treatment, Hypoglycemia, Insulin degludec
CLINICAL TRIAL Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice Kazuhiro Kobuke 1,
More informationSHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS
SHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS INDICATION Fiasp is indicated for the treatment of diabetes mellitus in adults. Special Note: DMAG has approved
More informationIDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes
primary care diabetes 10 (2016) 202 209 Contents lists available at ScienceDirect Primary Care Diabetes journal homepage: http://www.elsevier.com/locate/pcd Review IDegLira: Redefining insulin optimisation
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationPozivamo Vas da svojim sudjelovanjem i prikazom svog rada aktivno doprinesete uspjehu 1. Hrvatskog kongresa o psihotraumi.
Poštovane kolegice i kolege, Osobita mi je čast i zadovoljstvo pozdraviti Vas i zaželjeti Vam dobrodošlicu na 1. Hrvatskom kongresu o psihotraumi s međunarodnim sudjelovanjem. Tema kongresa, koji će se
More informationUltra-long-acting insulins: A review of efficacy, safety, and implications for practice
Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice Courtney S. Davis, PharmD, BCACP (Clinical Associate Professor), Joshua W. Fleming, PharmD, BCACP (Clinical Assistant
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationARTICLE. Keywords Basal-bolus insulin therapy. Day-to-day fasting plasma glucose variability. Insulin degludec. Insulin glargine.
Diabetologia (15) 58:13 19 DOI 1.17/s15-15-38-y ARTICLE Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre,
More informationEffect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus
Okada et al. Journal of Pharmaceutical Health Care and Sciences (215) 1:26 DOI 1.1186/s7-15-27-2 RESEARCH ARTICLE Open Access Effect of switching basal insulin regimen to degludec on quality of life in
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationUloga obiteljskog liječnika u prepoznavanju bolesnika s neuroendokrinim tumorom
Uloga obiteljskog liječnika u prepoznavanju bolesnika s neuroendokrinim tumorom Dr.sc. Davorin Pezerović OB Vinkovci 11.05.2017. For Za uporabu use by Novartisovim speakers predavačima and SAMO appropriate
More informationMonday 4 Dec Tuesday 5 Dec Wednesday 6 Dec Thursday 7 Dec Friday 8 Dec. Scientific Sessions. coffee break. Scientific Sessions
CONGRESS-AT-A-GLANCE Monday 4 Dec Tuesday 5 Dec Wednesday 6 Dec Thursday 7 Dec Friday 8 Dec 08.00 09.00 09.30 coffee break coffee break coffee break 10.00 Satellite Symposia 11.30 11.45 12.30 12.45 13.15
More informationImpact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
Diabetes Ther (2018) 9:2209 2218 https://doi.org/10.1007/s13300-018-0511-4 ORIGINAL RESEARCH Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety Paola Ponzani. Cesare
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tresiba 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution contains
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationSanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018
Sanofi Diabetes Update: New evidence reinforces favorable profile of Toujeo October 2, 2018 Background: For people with diabetes the early months of treatment with long-acting insulin are important for
More informationABSTRACT STUDY PROTOCOL
Diabetes Ther (2018) 9:2399 2406 https://doi.org/10.1007/s13300-018-0523-0 STUDY PROTOCOL Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tresiba 100 units/ml solution for injection in pre-filled pen Tresiba 200 units/ml solution for injection in pre-filled pen
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationA randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes
2017, 64 (2), 133-140 Original A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes Tatsuhiko Urakami, Yusuke
More informationIs Degludec the Insulin of Tomorrow?
5 : 6 Nihal Thomas, Ron Thomas Varghese, Vellore Abstract In an effort to develop better basal insulin with a profile that may cause less hypoglycaemia, ludec an analogue with a decanoic acid side chain
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More information1 ml solution contains 200 units insulin degludec* (equivalent to 7.32 mg insulin degludec).
פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר ביוני 2015 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals
More informationPriorities Advisory Committee
Insulin degludec (Tresiba ) PAC - Insulin degludec (Tresiba ) 2.1 The East of England Priorities Advisory Committee A function of GUIDANCE STATEMENT PAC Recommendations 1. Insulin degludec is NOT recommended
More informationWhen Should I Use Newer Insulins?
C H A P T E R 42 When Should I Use Newer Insulins? Paturi Vishnupriya Rao KEYWORDS Insulin analogues, newer insulins, hypoglycaemia, variability, flexibility BACKGROUND Diabetes is a major public-health
More informationABSTRACT. uncontrolled on basal insulin? OADs;
Diabetes Ther (2017) 8:673 682 DOI 10.1007/s13300-017-0252-9 BRIEF REPORT Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Ryzodeg 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution contains
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationoriginal article Introduction
original article Diabetes, Obesity and Metabolism 17: 1142 1149, 215. 215 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ORIGINAL ARTICLE Glycaemic control and hypoglycaemia
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationSteady state is reached within two to three days of once-daily. administration of degludec, a basal insulin with an ultra-long
Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action 1 Short title Insulin degludec: steady state within 2 3
More informationABSTRACT INTRODUCTION
Diabetes Ther (2017) 8:545 554 DOI 10.1007/s13300-017-0253-8 ORIGINAL RESEARCH Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016
More informationMETABOLIC CONTROL OF TYPE 1 DIABETES IN CHILDREN TREATED WITH INSULIN PUMP THERAPY
& METABOLIC CONTROL OF TYPE 1 DIABETES IN CHILDREN TREATED WITH INSULIN PUMP THERAPY Sniježana Hasanbegović*, Edo Hasanbegović Paediatric Clinic, University of Sarajevo Clinics Centre, Patriotske lige
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Ryzodeg 100 units/ml solution for injection in pre-filled pen Ryzodeg 100 units/ml solution for injection in cartridge 2. QUALITATIVE
More informationA Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
Clin Pharmacokinet (7) :9 DOI.7/s---7 REVIEW ARTICLE A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use Hanne Haahr Edmond
More informationImpact des nouvelles insulines dans la prise en charge du DT2
Impact des nouvelles insulines dans la prise en charge du DT2 Pr. A Avignon CHU Montpellier, Nutrition Diabète Université Montpellier 1, UFR Médecine INSERM U1046, CNRS UMR9214 @PrAvignon Antoine Avignon
More informationNew Medicine Assessment
New Medicine Assessment Insulin degludec plus liraglutide (Xultophy ) 100 units/ml insulin degludec plus 3.6 mg/ml liraglutide solution for injection in a pre-filled pen Treatment of adults with type 2
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationDiabetes Care Publish Ahead of Print, published online June 1, 2009
Diabetes Care Publish Ahead of Print, published online June 1, 2009 Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human
More informationCONTENT OVERVIEW. 1. Introduction 2. Objectives 3. Methods 4. Results 5. Conclusions
September 2017 COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC COMPARED WITH INSULIN GLARGINE U100 IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES FROM THE PERSPECTIVE OF THE SPANISH NATIONAL HEALTHCARE SYSTEM:
More informationI have no financial incentives or conflicts of interest to disclose for this presentation.
Jacob Lenzmeier, PharmD Resident Pharmacist-CentraCare Health November 9, 2017 1 I have no financial incentives or conflicts of interest to disclose for this presentation. 2 1 Review the mechanism of action,
More informationBasal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationPRODUCT INFORMATION RYZODEG 70/30 FLEXTOUCH RYZODEG 70/30 PENFILL NAME OF THE MEDICINE DESCRIPTION
Ryzodeg 70/30_pi1 Page 1 of 16 PRODUCT INFORMATION RYZODEG 70/30 FLEXTOUCH RYZODEG 70/30 PENFILL NAME OF THE MEDICINE Australian Approved Biological Name (ABN) Insulin degludec/insulin aspart Schematic
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationType 1 DM. CME Away India & Sri Lanka March 23 - April 7, 2018
Type 1 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017 by Sea
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationOTE HAR M A. Insulin degludec (Tresiba ): Ultralong. basal insulin with less nocturnal hypoglycemia than glargine.
HAR M A Vol. 31, Issue 5 February 2016 N OTE Established 1985 Insulin degludec (Tresiba ): Ultra-long basal insulin with less nocturnal hypoglycemia than glargine Brian Nocito, PharmD Candidate D iabetes
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationCOPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?
Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely? Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard
More informationHypoglycaemia can cause recurrent morbidity for patients with diabetes. The
supplement to Journal of the association of physicians of india january 2014 VOL. 62 35 Understanding the Safety of the New Ultra Long Acting Basal Insulin A Ramachandran 1, Vishal Gupta 2, Jothydev Kesavadev
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationrazionale della combinazione insulina/glp-1 RAs
Insulina e GLP-1 RAS: insieme o separati? razionale della combinazione insulina/glp-1 RAs Catania Mercure Catania Excelsior 10 ottobre 2017 Andrea Giaccari andrea.giaccari@unicatt.it Centro per le Malattie
More informationLearning Objectives. Are you ready for more insulin formulations?
Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations
More informationSAVE THE DATE NOVI IZAZOVI U HEMODINAMICI I INTENZIVNOJ MEDICINI
KLINIČKA BOLNICA DUBRAVA, ZAGREB, 8. - 9. OŽUJAK 2018. UNIVERSITY HOSPITAL DUBRAVA, ZAGREB, CROATIA, MARCH 8-9 2018 PRVA OBAVIJEST / FIRST ANNOUNCEMENT NOVI IZAZOVI U HEMODINAMICI I INTENZIVNOJ MEDICINI
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More information3. NEW DIAGNOSTIC CRITERIA, NEW CLASSIFICATION OF DM AND MODERN THERAPY APPROACH
3. NEW DIAGNOSTIC CRITERIA, NEW CLASSIFICATION OF DM AND MODERN THERAPY APPROACH 1.1 Introduction Ivana Pavlić-Renar, Ph.D. Vuk Vrhovac University Clinic, Zagreb, Croatia The current classification of
More informationInsulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
Diabetes, Obesity and Metabolism 14: 859 864, 2012. 2012 Blackwell Publishing Ltd Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type
More informationafter 52 weeks, with the intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, number NCT
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised,
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationCost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
Diabetes Ther (2018) 9:1919 1930 https://doi.org/10.1007/s13300-018-0478-1 ORIGINAL RESEARCH Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a
More informationCARDIO FORUM. Main Topics. 18 th -19 th May 2018 Grand Hotel 4 opatijska cvijeta Ul. Viktora cara Emina 6 Opatija, Croatia PROGRAMME
CARDIO FORUM Under auspices of: Organized by: PROGRAMME CROATIAN ACADEMY OF ARTS AND SCIENCE CROATIAN CARDIAC SOCIETY CROATIAN SOCIETY OF HYPERTENSION Interdisciplinary platform to discuss the optimal
More informationSTANDARDIZED EDUCATIONAL PROGRAM IN PERSONS WITH TYPE 2 DIABETES ON ORAL HYPOGLYCEMIC THERAPY: EFFECTS ON GLYCEMIC CONTROL AND BODY MASS INDEX
1 Vuk Vrhovac University Clinic Merkur University Hospital, Zagreb, Croatia 2 General Practice, Slatina, Croatia Original Research Article Received: October 21, 2010 Accepted: March 30, 2011 STANDARDIZED
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationQuando l insulina basale non basta più: differenti e nuove strategie terapeutiche
Quando l insulina basale non basta più: differenti e nuove strategie terapeutiche Giorgio Sesti Università Magna Graecia di Catanzaro Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationPreserved Pharmacokinetic Exposure and Distinct Glycemic Effects of Insulin Degludec and Liraglutide in IDegLira, a Fixed-Ratio Combination Therapy
Pharmacokinetics/Pharmacodynamics Preserved Pharmacokinetic Exposure and Distinct Glycemic Effects of Insulin Degludec and Liraglutide in IDegLira, a Fixed-Ratio Combination Therapy The Journal of Clinical
More information24 Hour Support. Telephone Available 24 hours a day, 7 days a week
Contents Page What is SHAIRE? 1 What is basal-bolus regimen? 2 Why do I need a basal-bolus regimen? 3 How does basal insulin work? 3 How does rapid-acting insulin work? 4 How often should I test my Blood
More informationStructure of Visits Persons with Diabetes in Croatian Family Practice Analysis of Reasons for Encounter and Treatment Procedures using the ICPC-2
Coll. Antropol. 30 (2006) 3: 495 499 Original scientific paper Structure of Visits Persons with Diabetes in Croatian Family Practice Analysis of Reasons for Encounter and Treatment Procedures using the
More informationTHE 3 rd CROATIAN SYMPOSIUM OF PEDIATRIC ANESTHESIOLOGISTS WITH INTERNATIONAL PARTICIPATION
THE 3 rd CROATIAN SYMPOSIUM OF PEDIATRIC ANESTHESIOLOGISTS WITH INTERNATIONAL PARTICIPATION VODICE, CROATIA, 5 th AND 6 th OF OCTOBER 2018, HOTEL OLYMPIA SKY Dear colleagues, guests and friends, We are
More information